Well Referenced

Tag: ER-positive breast cancer

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

This 2014 preclinical study investigates the combined effects of metformin and tamoxifen on estrogen receptor-positive (ER+) breast cancer cells. The combination therapy significantly inhibited cell proliferation, DNA replication, colony formation, and induced apoptosis more effectively than either agent alone. Mechanistically, the enhanced effects are associated with activation of the AMPK

Read More »
June 26, 2025 No Comments

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

This 2021 randomized pilot trial compared neoadjuvant everolimus plus letrozole (NET) with standard chemotherapy (FEC) in 40 postmenopausal women with ER-positive, HER2-negative breast cancer. The NET arm demonstrated a higher ultrasound response rate (65% vs. 40%) and better treatment completion (90% vs. 70%) compared to the FEC arm. Additionally, NET

Read More »
June 26, 2025 No Comments